Back
Entrada Therapeutics, Inc. 10K Form
Sell
44
TRDA
Entrada Therapeutics, Inc.
Last Price:
$11.83
Seasonality Move:
-22.18%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TRDA News And Ratings
See the #1 stock for the next 7 days that we like better than TRDA
TRDA Financial Statistics
Sales & Book Value
| Annual Sales: | $25.4M |
|---|---|
| Cash Flow: | $-32M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.00 |
| Price / Book: | 1.46 |
Profitability
| EPS (TTM): | -3.47090 |
|---|---|
| Net Income (TTM): | $-143.8M |
| Gross Margin: | $21.3M |
| Return on Equity: | -38.39% |
| Return on Assets: | -31.92% |
Entrada Therapeutics, Inc. Earnings Forecast
Key Entrada Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for TRDA is 83.89%.
-
The Selling, General & Administrative Expenses for TRDA have been equal to 161.48% of Gross Profit Margin.
-
The Research & Development expenses have been 536.85% of Revenue.
-
The Net Earning history of TRDA is -565.48% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 2 years.
Entrada Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | TRDA |
| Website: | entradatx.com |
Debt
| Debt-to-Equity Ratio: | 0.17 |
|---|---|
| Current Ratio: | 12.53 |
| Quick Ratio: | 12.17 |
Price-to-Earnings
| Trailing P/E Ratio: | 7.09 |
|---|---|
| Forward P/E Ratio: | 0 |
TRDA Technical Analysis vs Fundamental Analysis
Sell
44
Entrada Therapeutics, Inc. (TRDA)
is a Sell
Is Entrada Therapeutics, Inc. a Buy or a Sell?
-
Entrada Therapeutics, Inc. stock is rated a SellThe current Entrada Therapeutics, Inc. [TRDA] share price is $11.68. The Score for TRDA is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.